Clinical Approach to Manage Gastrointestinal Bleeding with a Left Ventricular Assist Device (LVAD)

Authors: Ahsan, I., Faraz, A., Mehmood, A., Ullah, W., and Ghani, A. R.

Cureus January 2019

Affiliations: Internal Medicine, Geisinger Health System, Danville, USA ; Internal Medicine, University of Buffalo, Buffalo, USA ; Internal Medicine, Geisinger Medical Center, Danville, USA ; Internal Medicine, Abington Hospital – Jefferson Health, Abington, USA ; Cardiovascular Medicine, Saint Louis University, Saint Louis, USA.

Abstract: Left ventricular assist devices (LVADs) are an exceedingly important form of mechanical support for patients with end-stage heart failure. LVADs can be utilized both as a bridge to cardiac transplant and also as a definitive treatment. However, a few complications are associated with LVAD placement, the most common and cumbersome of which is gastrointestinal (GI) bleeding with an incidence of about 30%. These bleeding events often require transfusion therapy, but they are rarely fatal. The etiologies of GI bleeding following LVAD are multifactorial and include unstable hemodynamics, an acquired von Willebrand factor (vWf) deficiency, impaired platelet aggregation, and activation of fibrinolytic systems. The treatment of choice in LVAD implantation-associated GI bleeding is endoscopy, which plays a vital role in both its diagnosis and management. Even so, its effectiveness in controlling post-LVAD implantation GI bleeding is still poorly ascertained. In this article, we will review the use of medication and alterations in the LVAD setting to prevent the occurrence of GI bleeding, as well as the findings of previously reported literature on LVAD implantation-associated GI bleeding.